Press Releases All News 2019 2018 2017 2016 2015 2014 Relmada Therapeutics Announces Promotion of Michael D. Becker to Chief Financial Officer May 16, 2016 Relmada Therapeutics Announces Results of In Vivo Study Showing d-Methadone has Antidepressant-like Effects May 4, 2016 Relmada Therapeutics to Present at the Joseph Gunnar "Pioneers 2016" Conference April 28, 2016 Relmada Therapeutics Provides Additional Details Regarding Upcoming R&D Day April 26, 2016 Relmada Therapeutics to Showcase Breadth of Pipeline at Upcoming R&D Day April 20, 2016 Relmada Therapeutics, Inc. Provides Update on Nasdaq Up-Listing Process April 14, 2016 Relmada Therapeutics to Present at the 28th Annual ROTH Conference March 8, 2016 Relmada Therapeutics Announces Publication of Full Results from Phase I Study Showing Treatment with d-Methadone to be Safe and Well Tolerated March 1, 2016 Relmada Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference February 2, 2016 Relmada Therapeutics Files Amended Complaint Against Laidlaw and Its Principals, Matthew Eitner and James Ahern January 26, 2016 « Previous 1 2 3 4 5 6 7 8 9 10 ...13 Next »
Relmada Therapeutics Announces Promotion of Michael D. Becker to Chief Financial Officer May 16, 2016
Relmada Therapeutics Announces Results of In Vivo Study Showing d-Methadone has Antidepressant-like Effects May 4, 2016
Relmada Therapeutics Announces Publication of Full Results from Phase I Study Showing Treatment with d-Methadone to be Safe and Well Tolerated March 1, 2016
Relmada Therapeutics Files Amended Complaint Against Laidlaw and Its Principals, Matthew Eitner and James Ahern January 26, 2016